Browsing Tag
Mesoblast
2 posts
Polynovo stock falls as diabetes wound trial results spotlight NovoSorb promise
Polynovo (ASX: PNV) shares slipped 1.37% as NovoSorb diabetes wound trial results showed faster healing in large wounds. Can reimbursement shifts revive growth?
FDA grants orphan drug exclusivity to Mesoblast’s Ryoncil for pediatric SR-aGvHD
Find out how Mesoblast's FDA approval for Ryoncil in pediatric SR-aGvHD sets a new benchmark in stem cell therapy and market exclusivity strategy.